for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

EXACT Sciences Corporation

EXAS.O

Latest Trade

103.02USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

35.25

 - 

110.74

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
103.02
Open
--
Volume
--
3M AVG Volume
36.92
Today's High
--
Today's Low
--
52 Week High
110.74
52 Week Low
35.25
Shares Out (MIL)
150.17
Market Cap (MIL)
16,088.93
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Exact Sciences Corp Earnings Release

Latest Developments

More

Exact Sciences And Pfizer Extend And Amend Cologuard Promotion Agreement

FDA Says Exact Sciences' Request To Update Instructions For Use Of SARS-Cov-2 Test Is Granted

Exact Sciences Q2 Loss Per Share $0.58

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About EXACT Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Industry

Biotechnology & Drugs

Contact Info

5505 ENDEAVOR LANE

MADISON, WI

53719

United States

+1.608.2845700

http://www.exactsciences.com

Executive Leadership

Kevin T. Conroy

Chairman of the Board, President, Chief Executive Officer

Jeffrey Thomas Elliott

Chief Financial Officer

D. Scott Coward

Senior Vice President, Chief Administrative Officer, General Counsel, Secretary

Graham Peter Lidgard

Senior Vice President, Chief Scientific Officer

Ana Hooker

Senior Vice President, Operations

Key Stats

1.31 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.5K

2019

0.9K

2020(E)

1.3K
EPS (USD)

2017

-0.990

2018

-1.430

2019

-0.640

2020(E)

-2.257
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.22
Price To Book (MRQ)
6.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
62.07
LT Debt To Equity (MRQ)
62.02
Return on Investment (TTM)
-5.58
Return on Equity (TTM)
-4.94

Latest News

Latest News

BRIEF-Exact Sciences Announces Publication Of Results Highlighting Performance Of Oncotype DX Genomic Prostate Score Result In Prostate Cancer

* EXACT SCIENCES CORP - ANNOUNCED PUBLICATION OF RESULTS HIGHLIGHTING PERFORMANCE OF ONCOTYPE DX GENOMIC PROSTATE SCORE RESULT IN PROSTATE CANCER Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Q1 Revenue $347.8 Mln Versus Refinitiv IBES Estimate Of $349.6 Million

* Q1 REVENUE $347.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $349.6 MILLION

BRIEF-Exact Sciences Corp Pauses certain clincial trial activities

* EXACT SCIENCES CORP - FOR THREE-MONTH PERIOD ENDED MARCH 31, 2020, CO SEES TOTAL REVENUE OF APPROXIMATELY $348M

BRIEF-Exact Sciences Takes Action During Covid-19 Pandemic

* EXACT SCIENCES CORP - WITHDRAWS PRIOR FIRST-QUARTER AND ANNUAL GUIDANCE FOR 2020 DUE TO COVID-19 IMPACT

BRIEF-Exact Sciences Corp Files Prospectus Supplement Relates To Resale Of Up To 533,763 Shares Of Common Stock By Selling Stockholders

* EXACT SCIENCES CORP FILES PROSPECTUS SUPPLEMENT RELATES TO RESALE OF UP TO 533,763 SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS Source text - (http://bit.ly/32TPLDp) Further company coverage:

BRIEF-Exact Sciences Announces Upsizing, Pricing Of 0.3750% Convertible Senior Notes Due 2028

* EXACT SCIENCES ANNOUNCES UPSIZING AND PRICING OF 0.3750% CONVERTIBLE SENIOR NOTES DUE 2028

Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal

Exact Sciences Corp <EXAS.O> said on Monday it will buy peer Genomic Health Inc <GHDX.O> for about $2.8 billion in cash and stock, expanding the cancer diagnostic company's testing capabilities to breast and prostate cancers.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 1300 GMT on Monday:

Exact Sciences to buy Genomic Health for $2.8 billion

Cancer diagnostics company Exact Sciences Corp said on Monday it will buy healthcare company Genomic Health Inc for about $2.8 billion to bolster its cancer testing business.

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

Cancer diagnostics company Exact Sciences Corp <EXAS.O> is in advanced negotiations to buy healthcare company Genomic Health Inc <GHDX.O> for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.

Exact Sciences surges after marketing deal with Pfizer for cancer test

Exact Sciences Corp's shares shot up as much as 26 percent on Wednesday after the company said Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer.

Exact Sciences signs marketing deal with Pfizer for cancer test

Exact Sciences Corp said on Wednesday Pfizer Inc would share marketing expenses and co-promote the company's stool screening test for colorectal cancer, in a bid to boost sales of the product.

American Cancer Society recommends earlier colorectal cancer screening

The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals.

BRIEF-Exact Sciences Says CEO Kevin T. Conroy's 2017 Total Compensation Was $13.3 Million

* EXACT SCIENCES CORP SAYS CEO KEVIN T. CONROY'S 2017 TOTAL COMPENSATION WAS $13.3 MILLION – SEC FILING Source : https://bit.ly/2w2gEbC Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Exact Sciences reports Q1 Loss Per Share of $0.33

* Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S

BRIEF-Mark Stenhouse To Join Exact Sciences As President, Cologuard

* MARK STENHOUSE TO JOIN EXACT SCIENCES AS PRESIDENT, COLOGUARD

BRIEF-Exact Sciences Q4 Loss Per Share $0.18

* ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018.

BRIEF-Exact Sciences announces upsize, pricing of $600 mln of 1 pct convertible senior notes due 2025

* EXACT SCIENCES ANNOUNCES UPSIZE AND PRICING OF $600 MILLION OF 1.0% CONVERTIBLE SENIOR NOTES DUE 2025

BRIEF-Exact Sciences Offers $500 Mln Convertible Senior Notes Due 2025

* EXACT SCIENCES ANNOUNCES OFFERING OF $500 MILLION CONVERTIBLE SENIOR NOTES DUE 2025 Source text for Eikon: Further company coverage:

BRIEF-Exact Sciences Says "Comfortable" With Current 2018 Consensus Revenue Estimate Of Around $417 Mln

* EXACT SCIENCES CORP SAYS "COMFORTABLE" WITH CURRENT 2018 CONSENSUS REVENUE ESTIMATE OF AROUND $417 MILLION Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up